NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Seaport Therapeutics

Seaport Therapeutics

Private
Boston, MassachusettsHealthcare & Life Scienceswww.seaporttx.com

Last Round

IPO

Apr 10, 2026

Est. Valuation

$733M

Total Funding Raised

$325M

Momentum

Top 10%

of companies Caplight tracks

Company Overview

Seaport Therapeutics is a biopharmaceutical company focused on developing innovative neuropsychiatric medicines that address significant patient needs while providing oral bioavailability to minimize side effects and enhance patient quality of life.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Mental Health, Clinical Trials

Business Model

B2B2C

Customer Profile

Revenue Share

AI Layer

Non-AI

Keywords

neuropsychiatric disordersoral drug deliveryGlyph platformlymphatic drug deliveryclinical stage pharmaMajor Depressive DisorderMDDoral bioavailabilitydepression treatmentCNS therapeuticsprodrugallopregnanolonedrug delivery platformneurosteroidfirst-pass metabolismGeneralized Anxiety DisorderGADanxiety treatmentneuroplastogen

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Seaport Therapeutics Comparables

Compare Seaport Therapeutics with similar companies based on industry and business-model similarity.

Seaport Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap

View Full Comparables Set

Access detailed peer comparisons, similarity scores, and market data.

Seaport Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
IPOApr 10, 2026
Series BOct 21, 2024
Series AApr 9, 2024

Key People

Founding team and executive leadership

Michael C. Chen

Co-founder, Chief Scientific Officer

Founding Team

Daphne Zohar

Founder, CEO Board Member

Founding Team

Eric Green

Chief Operating Officer

Executive Team

Seaport Therapeutics Investors

Notable investors and investment history

Seaport Therapeutics investors
InvestorRounds
CPP InvestmentsSeries B
Invus OpportunitiesSeries B
ARCH Venture PartnersSeries B, Series A
Foresite CapitalSeries B
T. Rowe PriceSeries B
Goldman Sachs Group, Inc.IPO
PureTech HealthSeries B, Series A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 10, 2026

    $100M raised in IPO round.

  • Mar 26, 2026

    New oral drug delivery technology developed with Monash University.

Seaport Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Seaport Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Seaport Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersBoston, Massachusetts
Employee Range63
Year Founded2020
Last FundingApr 10, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.